Last updated: September 18, 2026
The FDA approved Ultragenyx’s Fayuvi for Sanfilippo syndrome type A on September 17, two days before its September 19 action date. Bayer’s Kerendia added type 1 diabetes kidney disease, and Novo signed an up to $1.4 billion oral macrocycle pact with Orbis Medicines.
This page covers the Fayuvi approval and label, the Kerendia FINE-ONE data, the September 17 deal slate, the quiet end of Amylyx’s greenshoe window, Roche’s numberless Lunsumio confirmatory win, Thursday’s market moves, and the final scoreboard for the week’s forced disclosure calendar.
What did the FDA approve for Sanfilippo syndrome?
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), Ultragenyx Pharmaceutical’s gene therapy formerly known as UX111, on September 17, 2026. It is the first approved treatment for mucopolysaccharidosis type IIIA, also called Sanfilippo syndrome type A, a fatal pediatric neurodegenerative disease.
Per the company’s release, Fayuvi is a single dose intravenous AAV9 gene therapy that delivers a functional copy of the SGSH gene, addressing the enzyme deficiency that lets heparan sulfate accumulate in cells, including neurons. The approved label covers treatment of the neurologic manifestations of MPS IIIA in pediatric patients with preserved neurodevelopmental function.
| Fayuvi at approval | Detail (Ultragenyx release, September 17, 2026) |
|---|---|
| Pivotal evidence | Transpher A, up to 8 years of follow up; modified intention to treat group N=17 vs natural history cohort N=27 |
| Primary efficacy result | Bayley-III cognitive raw score 23.5 points higher than natural history (p<0.0001), ages 24 to 60 months |
| Biomarker | Reduction in cerebrospinal fluid heparan sulfate across all age groups |
| Most common adverse reactions | Liver enzyme increased (85%), vomiting (67%), abnormal behavior (56%), diarrhea (48%), pyrexia (41%) |
| Warnings | Hepatotoxicity, thrombocytopenia, thrombotic microangiopathy, hypersensitivity, potential malignancy risk, vector shedding for 3 months |
| Priority Review Voucher | Received upon approval (rare pediatric disease program) |
| Launch | Shipping to Qualified Treatment Centers expected within 30 to 60 days |
| Price | Not disclosed in the approval release |
The manufacturing detail matters more than usual. The FDA rejected UX111 in 2025 over manufacturing issues at Ultragenyx’s Bedford, Massachusetts facility and at third party manufacturer Andelyn Biosciences in Columbus, Ohio, per Fierce Pharma. The approved product is manufactured entirely in the United States at those same two sites, which means the resubmission cured the exact deficiencies that caused the rejection rather than moving the work elsewhere. The FDA accepted the resubmission in April under priority review. Fierce Pharma puts the MPS IIIA population at an estimated 3,000 to 5,000 patients in developed countries.
Why does a two day early approval matter?
Because it is the second time in six days the FDA has acted ahead of its own deadline. Fayuvi’s action date was September 19; the approval came September 17, two days early by our arithmetic from the two primary dates. Scholar Rock’s Isembyld was approved September 11, nineteen days ahead of its September 30 action date.
| Approval | Action date | Actual approval | Days early |
|---|---|---|---|
| Isembyld (apitegromab-mstn), Scholar Rock | September 30, 2026 | September 11, 2026 | 19 |
| Fayuvi (rebisufligene etisparvovec-hopf), Ultragenyx | September 19, 2026 | September 17, 2026 | 2 |
Days early figures are our arithmetic from primary dated documents in each case. Two data points are not a policy, but both approvals landed under the FDA’s new permanent CDER and CBER leadership, and both were rare disease files with prior regulatory friction. For anyone structuring positions around binary dates, the working assumption that agency action clusters on the PDUFA date itself is now demonstrably unreliable in both directions: the March 3 zanzalintinib extension pushed one decision out three months, and September has now produced two decisions that came early.
The tape added a wrinkle. Ultragenyx shares closed Thursday at 14.50, up 12.6 percent on the session, before the approval release crossed in the evening ahead of a 5:30 pm Eastern company call. Exchange close, our percentage arithmetic, and no cause assigned to the intraday move; Friday is the first full session in which the approval itself trades.
What did Bayer’s Kerendia get approved for?
The FDA approved Kerendia (finerenone) on September 17 to reduce urinary albumin to creatinine ratio in adults with chronic kidney disease associated with type 1 diabetes. Bayer’s release calls it the first new FDA approved treatment for this population in more than 30 years.
| FINE-ONE (Phase 3) | Result (Bayer release, September 17, 2026) |
|---|---|
| Enrollment | 242 adults with CKD associated with type 1 diabetes |
| UACR at month 3 | 22% reduction vs placebo |
| UACR at month 6 | 28% reduction vs placebo (p=0.0001) |
| Treatment emergent adverse events | 47.1% vs 49.2% placebo |
| Serious adverse events | 11.8% vs 11.5% placebo |
| Hyperkalemia | 10.1% vs 3.3% placebo; discontinuation 1.7% vs 0% |
This is the fourth Kerendia indication, following CKD associated with type 2 diabetes in 2021 and the 2025 heart failure approvals, per Fierce Pharma, which also reports Q2 2026 Kerendia sales grew 83 percent year over year against a roughly $3 billion peak sales projection. The label expansion is built on a surrogate: UACR reduction, which the FDA accepts as reasonably likely to predict slower eGFR decline and end stage kidney disease. The type 1 population has been structurally excluded from the last three decades of diabetic kidney disease approvals, which were run in type 2 patients, so a 242 patient surrogate trial was enough to close a gap that outcomes trials never addressed.
What happened to Amylyx’s $500 million offering window?
Nothing, and that is the story. The 30 day option window from Amylyx’s August 19 underwriting agreement reached its expiry this week with no disclosure of an exercise, based on our check of the company’s SEC filings, newsroom, and wire coverage as of Thursday night, September 17.
| Amylyx offering fact | Detail (August 20, 2026 Form 8-K) |
|---|---|
| Firm shares | 14,090,000 at $35.50 per share |
| Option shares (30 days) | Up to 2,113,500 additional |
| Expected net proceeds | ~$471.7M firm; ~$542.5M if the option were exercised in full |
| Firm closing | Expected on or about August 21, 2026 |
| Use of proceeds | Potential avexitide US launch, manufacturing capacity, R&D, general corporate purposes |
AMLX closed Thursday at 33.94, up 4.0 percent on no news we could find, and that close was the fourteenth consecutive session below the $35.50 offer price since pricing. An underwriters’ option is only worth exercising when the market trades above the offer price; fourteen straight closes below it left the option without economic purpose. The disclosure the calendar was supposed to force never needed to arrive, because the tape had already answered the only question the disclosure would have settled. The roughly $70.8 million difference between the firm and full exercise proceeds figures in the 8-K is the measure of what the window’s silent expiry cost. Avexitide’s NDA remains guided for submission by year end.
What deals were signed this week?
Thursday produced three discovery stage platform deals, and a fourth from Monday completes the picture. All follow the same shape: modest money now, large contingent back ends, and pharma buying access to a screening or design engine rather than a drug.
| Deal | Structure | What is being bought | Source |
|---|---|---|---|
| Novo / Orbis Medicines (Sept 17) | Up to $1.4B in upfront and potential development and commercial milestones, plus tiered royalties and a strategic equity investment; upfront not broken out | Multi target oral macrocycle discovery (nGen platform), cardiometabolic targets | Orbis release |
| Roche / Dualitas Therapeutics (Sept 17) | $36.5M upfront; up to ~$1B with milestones; tiered royalties, per Fierce Biotech | DualScreen functional screening of 300,000+ bispecific target pairs, immunology and inflammation | Fierce Biotech |
| SK Biopharmaceuticals / 1ST Biotherapeutics (Sept 17) | $1.8M upfront, $1.8M near term, milestones totaling $314.8M combined, royalties, plus a separate $2.2M equity investment, per Fierce Biotech | 1ST-104, oral dual LRRK2 and c-Abl inhibitor, preclinical Parkinson’s disease | Fierce Biotech |
| GSK / Chimagen Biosciences (Sept 15) | Up to $750M, per BioSpace | Trispecific T cell engager | BioSpace |
The Orbis deal is Novo’s second platform move in a week of cardiometabolic pipeline rebuilding after the ziltivekimab trial halts and the Ascendis termination, and it keeps the money inside the family: Orbis is a Copenhagen biotech founded in the Novo Holdings orbit that has raised about €116 million since 2024, per Fierce Biotech. The structure disclosure is deliberately vague in the release, which states only the $1.4 billion ceiling; we are not printing an upfront figure because none exists in the public record. The SK deal is the starkest version of the shape: $1.8 million buys a preclinical Parkinson’s program with almost all of the roughly $315 million total contingent on milestones, per Fierce.
What did Roche’s Lunsumio confirmatory trial show?
Roche said on September 17 that Celestimo, the Phase 3 confirmatory trial of Lunsumio (mosunetuzumab) plus lenalidomide versus rituximab plus lenalidomide in follicular lymphoma patients with at least one prior line, met its progression free survival primary endpoint with a statistically and clinically meaningful improvement. No figures were disclosed; overall survival data were immature.
The result is designed to convert Lunsumio’s accelerated approval in third line follicular lymphoma to full approval and to support a move into the second line setting. It is also the newest entry in the withholding column of this week’s ledger: a positive pivotal readout announced with zero numbers, joining BMS’s arlo-cel and Amgen’s DeLLphi-305 in the pattern where the print is saved for a congress and the market is asked to trade the adjective. Coverage from Fierce Pharma, on the basis of Roche’s release.
How did the forced disclosure week actually end?
The week’s setup was five events where calendars, contracts, or regulators appeared to force information into the open. Here is the final scoreboard.
| Forcing event | Expected disclosure | What actually happened |
|---|---|---|
| Ultragenyx UX111 PDUFA (Sept 19) | Approval decision by Friday | Approved Thursday, two days early, with a PRV; price not disclosed |
| Amylyx greenshoe window (~Sept 18) | Closing and exercise disclosure | Window reached expiry silent; fourteen closes below $35.50 made the option worthless (scope: SEC, newsroom, wires, checked Sept 17 night) |
| Amgen at Morgan Stanley (Sept 15) | OCEAN(a) window, DeLLphi-305 venue | Neither named; our FAIL grade stands with no second account of the session all week |
| Isembyld pricing (post Sept 11 approval) | A primary price document | Still none as of Sept 17 night; conflicting trade characterizations stand attributed |
| Grail adcomm briefing documents (~Sept 21) | FDA briefing package | Not yet posted as of Sept 17 night; only two conflict waiver PDFs on the meeting page |
Two of five forcing events produced documents, and both came from the FDA, early. None of the three corporate disclosures arrived. Vera Therapeutics, which printed its complete ORIGIN 3 dataset Tuesday including dates, watched its stock round trip: down two sessions on record data, then back up 7.9 percent Thursday to 34.27 with no new disclosure, above the 34.05 close that preceded the print.
What moved in biotech markets on Thursday?
Thursday was broadly green across the sector, with several outsized moves that had no company disclosures behind them that we could find. All prices are exchange closes; percentage moves are our arithmetic against Wednesday closes; no causes assigned unless a disclosure is cited.
| Ticker | Thursday close | Move | Note |
|---|---|---|---|
| RARE | 14.50 | +12.6% | Closed before the evening Fayuvi release; Friday is the first full reaction session |
| BHVN | 13.89 | +15.6% | No release found (company newsroom and search checked Sept 17 night) |
| GENB | 17.12 | +9.2% | No disclosure found |
| VERA | 34.27 | +7.9% | No new disclosure; recovers the two session post data fade |
| GRAL | 79.95 | +6.4% | No disclosure found; panel Sept 23 |
| IONS | 46.75 | +4.3% | Three session slide ended without news |
| AMLX | 33.94 | +4.0% | Fourteenth consecutive close below $35.50 |
| DFTX | 38.68 | +2.2% | 21 cents below the 38.89 pre readout close |
| BBNX | 21.43 | −3.4% | Two day post clearance run ended; no new disclosure |
| SRRK | 49.02 | −0.7% | Fourth straight post approval decline; no cause assigned |
Elsewhere in the tracked cohort: AMGN 379.78 (+0.9%), NVS 140.92 (+1.6%), NVO 43.19 (+3.4%), AZN 166.14 (+2.0%), BMY 62.84 (−1.2%), GILD 150.89 (+2.2%), VRTX 516.34 (+0.6%), LLY 1152.44 (+1.3%), EXEL 58.49 (+3.0%), MRK 147.15 (+1.5%), SMMT 17.72 (+2.4%), CGEM 21.36 (+3.5%), LEGN 17.58 (+3.4%), SION 7.18 (+2.0%), CTNM 13.21 (−4.0%), CRBP 7.26 (flat), BSX 43.55 (−0.8%), QURE 44.09 (flat). Electra Therapeutics raised $350 million in its IPO per Endpoints News; ETRA had not traded by Thursday’s close, so there is no market print yet, and the company’s own pricing release had not surfaced in our checks Thursday night.
What else happened on September 17?
Lisata Therapeutics and Marea Therapeutics agreed to a stock for stock merger backed by a $225 million private placement, with Marea investors owning 59.5 percent and current Lisata holders 2.4 percent of the combined company, which keeps the Lisata name and advances MAR001 in severe hypertriglyceridemia and MAR002 in acromegaly, per Fierce Biotech. Endpoints News counts the Marea and North Immunology reverse mergers at $405 million in combined backing. Medtronic launched the exchange offer that completes its MiniMed separation on September 14, offering to swap up to 80.1 percent of its remaining 89.9 percent stake at a 7 percent discount through October 9, per MedTech Dive. Sionna Therapeutics’ restructuring reached 46 percent of staff per BioSpace’s layoff tracker. GSK is laying off about 650 employees as it closes its Dresden vaccine manufacturing site, per BioSpace. Cellares signed its first Asian partnership, with Taiwan’s GenomeFrontier Therapeutics, per Endpoints. And the FDA’s September 15 launch of its Expedited IND Pilot, with applications due October 30, is now confirmed by an agency press announcement.
What should investors watch next week?
The Grail briefing documents are the next forcing event: expected around September 21 ahead of the September 23 Molecular and Clinical Genetics Panel on the Galleri PMA, the first FDA advisory committee on a multi cancer early detection test. As of Thursday night the meeting page still carries only two waiver PDFs. AbbVie’s full CERVINO data on etentamig comes September 25. The Section 232 pharmaceutical tariff date is September 29, and the GENEROUS Medicaid MFN opt in deadline is September 30. GSK’s own window for starting its Phase 3 flu vaccine efficacy trial, stated as this month, has about two weeks left. Fayuvi’s first commercial shipments, and any price disclosure, land inside 30 to 60 days.
Frequently asked questions
What is Fayuvi?
Fayuvi (rebisufligene etisparvovec-hopf), formerly UX111, is Ultragenyx’s single dose intravenous AAV9 gene therapy for the neurologic manifestations of MPS IIIA (Sanfilippo syndrome type A), approved by the FDA on September 17, 2026 as the first treatment for the disease.
What is Sanfilippo syndrome type A?
A rare inherited lysosomal disease in which SGSH gene mutations leave heparan sulfate to accumulate in cells, driving progressive childhood neurodegeneration, loss of speech and mobility, and early death. Fierce Pharma estimates 3,000 to 5,000 patients in developed countries.
How well did Fayuvi work in its pivotal study?
In Transpher A, 17 treated patients scored 23.5 points higher than a 27 patient natural history cohort on the Bayley-III cognitive raw score (p<0.0001), with cerebrospinal fluid heparan sulfate reduced across age groups, per Ultragenyx’s release.
How much does Fayuvi cost?
Ultragenyx did not disclose a price in its approval release. Commercial product is expected to ship to Qualified Treatment Centers within 30 to 60 days, which is the window in which pricing should surface.
Why was UX111 rejected in 2025?
The FDA cited manufacturing issues at Ultragenyx’s Bedford, Massachusetts facility and at third party manufacturer Andelyn Biosciences, per Fierce Pharma. The approved product is made at those same US sites, meaning the deficiencies were remediated in place.
Did Ultragenyx get a Priority Review Voucher?
Yes. The company confirmed it received a rare pediatric disease Priority Review Voucher upon Fayuvi’s approval. Recent PRV sales have commanded well over $100 million, though the company has not stated monetization plans.
Why did the FDA approve Fayuvi before its PDUFA date?
The agency did not say. It is the second early action in six days after Isembyld’s September 11 approval, nineteen days ahead of its date, suggesting the review queue under the new permanent CDER and CBER directors is running ahead of its published deadlines on some files.
What is Kerendia now approved for?
Four indications: CKD associated with type 2 diabetes, two 2025 heart failure indications, and now reducing UACR in adults with CKD associated with type 1 diabetes, where Bayer calls it the first new FDA approved treatment in more than 30 years.
What did the FINE-ONE trial show?
In 242 adults with type 1 diabetes associated CKD, finerenone cut UACR 22 percent versus placebo at month 3 and 28 percent at month 6 (p=0.0001), with hyperkalemia at 10.1 percent versus 3.3 percent, per Bayer’s release.
What is Orbis Medicines and what did Novo buy?
Orbis is a Copenhagen biotech using its nGen platform to design oral macrocycles, ring shaped molecules that can hit targets usually needing injected biologics. Novo signed a multi target cardiometabolic discovery pact worth up to $1.4 billion in upfront and milestones plus royalties and an equity investment.
Did Amylyx’s underwriters exercise their option?
No disclosure of an exercise had surfaced as of Thursday night September 17, with the 30 day window from the August 19 underwriting agreement at its expiry, and AMLX has closed below the $35.50 offer price in all fourteen sessions since pricing, leaving the option without economic value.
What is the difference between Lunsumio’s current and potential label?
Lunsumio holds accelerated approval as third line follicular lymphoma monotherapy. The Celestimo win, if the data hold, supports conversion to full approval and a lenalidomide combination label one line earlier. Roche has not yet disclosed the trial’s figures.
When is the Grail advisory committee?
September 23, 2026: the FDA’s Molecular and Clinical Genetics Panel reviews Grail’s Galleri PMA, the first advisory committee on a multi cancer early detection blood test. Briefing documents were not yet posted as of September 17 night.
What happened with Electra’s IPO?
Endpoints News reports Electra Therapeutics raised $350 million, the 21st biotech IPO of 2026, to fund a Phase 2/3 trial of ipsoprubart in secondary hemophagocytic lymphohistiocytosis. The shares had not traded by Thursday’s close and the company’s pricing release had not surfaced in our checks.
Sources
Primary sources: Ultragenyx press release, September 17, 2026 (Fayuvi approval, Transpher A data, PRV, launch timing). Bayer US press release, September 17, 2026 (Kerendia approval, FINE-ONE data). Orbis Medicines press release, September 17, 2026 (Novo partnership terms). Amylyx Form 8-K, filed August 20, 2026 (offering and option terms). FDA advisory committee meeting page for the September 23, 2026 Molecular and Clinical Genetics Panel (materials status, checked September 17 night). FDA press announcements index, September 15, 2026 (Expedited IND Pilot).
Trade press, September 15 to 17, 2026: Fierce Pharma (Fayuvi approval context, Kerendia context, Lunsumio Celestimo readout, Novo CEO interview). Fierce Biotech (Novo/Orbis context, Roche/Dualitas terms, SK Biopharmaceuticals/1ST Biotherapeutics terms, Lisata/Marea merger). Endpoints News (Electra IPO, reverse merger backing total, Cellares and Ori Biotech items). BioSpace (GSK/Chimagen deal, GSK Dresden layoffs, Sionna layoff tracker, Operation TrialBlazer). MedTech Dive (Medtronic MiniMed exchange offer, dated September 14).
Market data: exchange closes for Thursday, September 17, 2026; percentage moves are our arithmetic against Wednesday closes; no cause assigned to moves without a company disclosure.
Related coverage
- Vera’s Trutakna cut kidney disease progression risk 76% over two years as Novartis ended an ALS program and bought a brain delivery platform (September 17)
- Amgen named no readout dates at Morgan Stanley as the FDA approved the first Lutathera equivalent (September 16)
- Scholar Rock’s Isembyld won FDA approval 19 days early (September 15)
- AstraZeneca’s Etcamah missed its first line trial eight days after FDA approval (September 14)
- Amylyx priced an upsized $500.2M offering: the week’s binary ledger tally (August 21)
